Early-generation kinase medicines are limited by poor selectivity, off-target effects and the emergence of resistance.

Our founding scientists envisioned a new generation of highly selective kinase medicines that could prolong lives, improve quality of life and prevent disease recurrences, with more potent target inhibition, fewer off-target effects and opportunities for therapeutic combinations.

They worked to build a scalable platform that could yield multiple selective kinase medicines for a wide range of diseases, bringing this innovation to as many patients as possible.

A look inside our labs

Our scientists merge expertise in bioinformatics and structural and cell biology, world-class drug design capabilities and a proprietary library of novel compounds to create a new discovery paradigm. This unique approach enables us to rapidly identify compelling disease targets and design highly selective kinase medicines.

The result is a robust and diverse portfolio of clinical- and research-stage programs targeting genomically defined cancers, rare diseases and cancer immunotherapy. With a steadfast commitment to scientific excellence and to patients, we aim to rapidly and unequivocally change the face of medicine.

Meet our Scientists

Tyler//
Ludivine//
Dean//
Luz//

Tyler Rouskin-Faust: Scientist II

My path

I received my B.S. in Biology from the University of Missouri in 2009. For my graduate work, I studied in the lab of Dr. Alan Frankel at UCSF, obtaining a Ph.D. in 2016. Finally, I was a post-doctoral fellow in the lab of Dr. Eric Fischer at Dana-Farber Cancer Institute until 2020.

My experience

My doctoral and post-doctoral studies were focused on aspects of protein degradation. I learned that Blueprint was entering into targeted protein degradation, and I was excited about the opportunity of joining and helping build a nascent effort at a company with a strong track record of bringing medicines to patients.

My biggest achievement

Coming into my postdoc, I had no structural biology experience but wanted to have a better understanding of the discipline. Over my three and a half years of training at Dana-Farber, several colleagues and I were able to solve the structure of an important protein-small molecule complex, which demonstrated that molecular glue degraders (MGD) were more common than the research community anticipated. On a personal level, this achievement also reinforced the idea that with focused effort and learning, daunting new challenges can always be overcome.

My Blueprint Medicines

I joined Blueprint because of the intense commitment to and record of success in bringing targeted medicines to patients in need.

Ludivine Moine: Scientist I, Medicinal Chemistry

My path

I earned a chemical engineering degree from CPE Lyon, France and a M.Sc. in organic chemistry at the University of Montreal, Canada.

My experience

I worked in a big pharma in oncology for many years using different modalities, but I never worked with kinases. I wanted to work for a precision medicine company that specialized in this area and is fully dedicated to discovery. Blueprint Medicines naturally fit the bill.

I was also attracted to Blueprint by the company’s values and its focus on quickly delivering life-changing therapies, and I saw an amazing opportunity for growth and no glass ceiling.

My biggest achievement

I recently contributed to the design and synthesis of multiple research candidates during the COVID-19 pandemic. These efforts offer an opportunity to potentially benefit more patients who harbor specific mutations by targeting the underlying genetic drivers of their disease.

My Blueprint Medicines

Blueprint is a pioneer in precision medicine, and I wanted to learn from the inside how the company has been able to provide innovative therapies to patients in record time. Our core values also resonate with me, and I specifically enjoy how deeply Blueprint invests in discovery and selects targets that may make the most and fastest impact on patients’ lives. Lastly, the collaborative, dynamic, diverse and empowering environment has been another big factor. I believe I can accomplish anything here, and I get the full support of my team to be the best version of myself.

Dean Zhang: Senior Scientist, Biochemistry and Biophysics

My path

I was trained as a biochemist and chemical biologist in Dr. Peter Tonge’s group at Stony Brook University. During my five years of Ph.D. training, I tried to understand how drug molecules interact with their protein targets, and how this interaction quantitively translates into drug efficacy.

My experience

After my Ph.D., I joined a pharmaceutical company as a biochemist. There, I was exposed to many different drug discovery projects and learned how to best use my biochemistry background to help discover novel drug molecules. A couple of years in, just when I started doubting if I will ever see a drug that I’ve worked on make it to patients, a biochemist position opened at Blueprint Medicines. I said to myself that this is a rare opportunity where I can work in one of the best small molecule drug discovery organizations, and it might be my best shot to ever deliver a drug to patients. So, I applied and joined.

My biggest achievement

I feel incredibly lucky to be able to apply my background to do a job that’s extremely meaningful and super exciting. It’s already quite an achievement to equip yourself with deep knowledge in any scientific area, but it takes a lot of hard work, perseverance, bravery and more to continue down this road of science and eventually use this knowledge to do a job as meaningful as helping save people’s lives. It sounds like a dream come true because it is a dream that came true.

My Blueprint Medicines

I joined Blueprint because the company stays true to science and has found a way to do drug discovery very efficiently. As a drug discovery scientist, I’ve always dreamt of developing medicines that can impact people’s lives, and Blueprint is the place where I can not only realize this goal, but also do it quickly and many times over.

Luz Tavera-Mendoza: Senior Scientist, Biology

My path

I completed my Ph.D. at McGill University in Montreal, Canada in the department of Experimental Medicine and my postdoctoral fellowship at the Dana-Farber Cancer Institute of Harvard Medical School in the department of Molecular Oncology.

My experience

My research experience on cellular and molecular biology in the specific context of cancer ultimately led me to Blueprint Medicines.

My biggest achievement

One of my biggest achievements is being the first one to describe that an herbicide previously thought to be safe had the capacity to be an endocrine disruptor at the city of Montreal’s drinking water levels. I joined a large group of scientists who were involved in eventually having this herbicide banned from North America, Europe and Australia. This was very important to me because it helped protect many people’s health as well as the environment.

I also helped uncover a mechanism by which a vitamin D dietary supplementation can help prevent the most common subtype of breast cancer. This is important because most women in the Northern hemisphere have a vitamin D deficiency, and incorporating this small habit can make a substantial impact on women’s health.

My recent scientific publications

Vitamin D receptor regulates autophagy in the normal mammary gland and in luminal breast cancer cells,” published in the Proceedings of the National Academy of Sciences in 2017

Vitamin D receptor as a master regulator of the c-MYC/MXD1 network, published in the Proceedings of the National Academy of Sciences in 2012

Genome-wide approaches for identification of nuclear receptor target genes,” published in Nuclear Receptor Signaling in 2006

See Luz's other publications

My Blueprint Medicines

“Patients First” is our most important value. Every scientist working here at Blueprint Medicines shares an intense commitment to making a difference for patients.

Tyler
Ludivine
Dean
Luz

“We’re entering a new era of precision medicine… we can now rapidly and reproducibly design potent and selective kinase medicines for previously undruggable as well as newly discovered drivers of disease. Combined with recent advances in molecular profiling, we believe these next-generation kinase medicines can quickly achieve clinical proof-of-concept and, ultimately, transform patient care.”

Fouad Namouni, M.D., President, Research & Development

Scientific Advisory Board

Giulio Draetta, M.D., Ph.D.

Director, Institute for Applied Cancer Science at MD Anderson Cancer Center, and Professor of Molecular and Cellular Oncology

Brian Druker, M.D.*

Director, Oregon Health & Science University Knight Cancer Institute, and JELD-WEN Chair of Leukemia Research

Carlos Garcia-Echeverria, Ph.D.

Global Head of Research Platforms, Sanofi

Scott Lowe, Ph.D.*

Member, Cancer Biology and Genetics Program at Memorial Sloan Kettering Institute Cancer Center, and Chair, Geoffrey Beene Cancer Research Center

Nick Lydon, Ph.D.*

Founder, Granite Biopharma LLC

Charles L. Sawyers, M.D.*

Director, Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center